Evidence map›Paper›PMID 41563678›Full record

ReviewMedical oncology (Northwood, London, England)2026

Thioredoxin-Binding protein 2 and apoptosis Signal-Regulating kinase 1: redox stress sensors and therapeutic targets in hepatocellular carcinoma.

Nishat Afroz, Arif Ahmad, Abul Vafa, Rupali Ghosh, Saima Wajid

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nishat Afroz *Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India.
Arif Ahmad *Department of Zoology, School of Sciences, Maulana Azad National Urdu University, Gachibowli, Hyderabad, 500032, Telangana, India.
Abul VafaDepartment of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India.
Rupali GhoshDepartment of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India.
Saima WajidDepartment of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India. swajid@jamiahamdard.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) develops under sustained oxidative and inflammatory stress, where thioredoxin-binding protein 2 (TBP2/TXNIP) and apoptosis signal-regulating kinase 1 (ASK1/MAP3K5) act as central redox sensors. Under basal conditions, TBP2 inhibits reduced thioredoxin, enabling ASK1 activation and c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK) signaling to promote apoptosis, senescence, and immune surveillance. In HCC, transcriptional repression, epigenetic silencing, and post-transcriptional regulation downregulate TBP2 and ASK1, fostering tumor cell survival, metabolic adaptation, and immune evasion. Both proteins intersect with the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, which induce pyroptosis and provides antitumor immunity. This review synthesizes current mechanistic insights into TBP2/ASK1 regulation, their integration with redox and inflammasome signaling, and modulation by natural compounds such as curcumin, piperine and other natural compounds. We also examine therapeutic approaches including gene therapy, epigenetic reactivation, and redox-modulating agents. Translational challenges include context-dependent effects, biomarker limitations, and delivery specificity. Refining strategies to achieve precise, transient TBP2/ASK1 activation may unlock their tumor-suppressive potential while minimizing inflammatory risk, offering a novel avenue for HCC treatment.

Indexed as

Carcinoma, HepatocellularCarrier ProteinsLiver NeoplasmsMAP Kinase Kinase Kinase 5ThioredoxinsAnimalsApoptosisHumansOxidation-ReductionOxidative StressCarrier ProteinsMAP3K5 protein, humanMAP Kinase Kinase Kinase 5ThioredoxinsTXNIP protein, humanASK1Hepatocellular carcinomaNLRP3 inflammasomeOxidative stressTBP2

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.